Country: Stati Uniti
Lingwa: Ingliż
Sors: NLM (National Library of Medicine)
THEOPHYLLINE ANHYDROUS (UNII: 0I55128JYK) (THEOPHYLLINE ANHYDROUS - UNII:0I55128JYK)
Pharmaceutical Associates, Inc.
THEOPHYLLINE ANHYDROUS
THEOPHYLLINE ANHYDROUS 80 mg in 15 mL
ORAL
PRESCRIPTION DRUG
Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. Theophylline oral solution is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.
Theophylline oral solution is a clear red solution with a mixed fruit flavor. Each tablespoonful (15 mL) contains 80 mg theophylline anhydrous. Theophylline oral solution is available in the following oral dosage form: NDC 0121-4794-15 (Unit dose cups of 15 mL, 10 cups per tray). Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in tight container.
Abbreviated New Drug Application
THEOPHYLLINE- THEOPHYLLINE ANHYDROUS SOLUTION PHARMACEUTICAL ASSOCIATES, INC. ---------- THEOPHYLLINE ORAL SOLUTION RX ONLY DESCRIPTION Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Anhydrous theophylline has the chemical name 1H-Purine- 2,6-dione, 3,7- dihydro-1,3 -dimethyl-, and is represented by the following structural formula: The molecular formula of anhydrous theophylline is C H N O with a molecular weight of 180.17. Theophylline oral solution is available as a liquid intended for oral administration, containing 80 mg of theophylline anhydrous and 20% alcohol in each 15 mL (tablespoonful). Theophylline oral solution also contains the following inactive ingredients: citric acid, FD&C Red No. 40, glycerin, saccharin sodium, imitation tutti frutti fruit flavor and purified water. Theophylline oral solution has a pH of 3.0 - 4.0. CLINICAL PHARMACOLOGY MECHANISM OF ACTION Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilatation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow). Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an ade Aqra d-dokument sħiħ